FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322760544> ?p ?o ?g. }

• W4322760544 endingPage "01" @default.
• W4322760544 startingPage "OT3" @default.
• W4322760544 abstract "Abstract Background: Breast cancer patients with mutation(s) in the PIK3CA gene have more aggressive disease and worse outcomes relative to patients without PIK3CA mutations. Alpelisib (Piqray), an inhibitor of PIK3CA, was approved for breast cancer patients with PIK3CA mutations. An on-target toxicity of alpelisib is hyperglycemia leading to hyperinsulinemia which may limit effectiveness of this drug. Patients with baseline metabolic dysfunction, insulin resistance, and/or elevated HbA1c are at greater risk of developing grade 3,4 hyperglycemia after receiving alpelisib (Piqray) than patients without metabolic dysfunction. Restoring insulin sensitivity and reducing systemic insulin levels improved the efficacy of alpelisib in preclinical models of breast cancer. Evexomostat is a polymer-drug conjugate of a novel small molecule methionine aminopeptidase 2 (MetAP2) inhibitor that in normal mice reduced alpelisib-induced hyperglycemia/hyperinsulinemia and in the MCF-7 model of HR+/PIK3CA-mutant breast cancer showed synergistic anti-tumor activity with alpelisib (Piqray). Evexomostat was well-tolerated in a phase 1 monotherapy safety study in late-stage cancer patients and improved insulin resistance in patients with elevated insulin at baseline, among other metabolic and angiogenic markers. Methods: This is a phase 1b/2, open-label, single-arm pilot study (NCT05455619) in postmenopausal women with PIK3CA-mutated, HR+, HER2- metastatic breast cancer with disease progression following treatment with endocrine therapy plus a CDK4/6 inhibitor who are at risk for hyperglycemia, with risk factors defined as HbA1c between 5.7 and 6.4% and/or HOMA-IR ≥1.8. The primary objective is to determine the safety of evexomostat plus standard of care treatment alpelisib (Piqray) and fulvestrant (combined, the ‘triplet therapy’), to measure the severity and number of hyperglycemic events, and to assess clinical, anti-tumor benefit of the triplet therapy. The trial will begin with a dose-escalation cohort (n=6) at an evexomostat dose of 36 mg/m2 (one dose below the monotherapy MTD of 49 mg/m2) in combination with alpelisib and fulvestrant given in accordance with their respective labels. Based on safety data from the first 6 patients (two cycles), the safety review committee may increase the evexomostat dose for the next cohort of six patients to 49 mg/m2 or may decrease the evexomostat dose to 27 mg/m2 and may adjust the dose of alpelisib if warranted. Once the MTD of the triplet therapy has been defined, additional enrollment will occur until a total of up to 20 patients have completed at least two cycles of triplet therapy at that dose. If warranted, an additional 20 patients may be enrolled to further characterize the safety profile and/or anti-tumor effect of the triplet therapy (total of up to 52 patients). This trial will open to accrual in August, 2022. Primary safety analysis consists of the type, frequency, and severity of treatment-emergent adverse events (TEAEs) per the NCI CTCAE, v5.0, the number of patients with grade 3 or 4 hyperglycemia during the first 2 cycles of therapy plus an estimate of the proportion and its exact upper one-sided 97.5% confidence bound will be analyzed. Efficacy analyses include calculation of the ORR, consisting of complete response (CR) and partial response (PR). The number of patients alive without disease progression six months from the start of the triplet therapy will be assessed. The CBR of CRs, PRs plus stable disease ≥24 weeks from C1D1 will be calculated. Overall survival data will be summarized as available or appropriate. QoL will be analyzed according to functional scores and recommendations in the EORTC scoring manual. ECOG performance status and change from baseline will be summarized. Citation Format: Peter Cornelius, Neal Salomon, David Browning, Sakirat Gill, Ben Mayes, Pierre Dufour, James Shanahan, Bradley Carver, Hope Rugo. The Amelia-1 Study: A phase 1b/2 trial of evexomostat (SDX-7320) plus fulvestrant (Faslodex®) and alpelisib (Piqray®) in patients with advanced breast cancer at risk for alpelisib (Piqray)-induced hyperglycemia [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr OT3-31-01." @default.
• W4322760544 created "2023-03-03" @default.
• W4322760544 creator A5000260923 @default.
• W4322760544 creator A5002767668 @default.
• W4322760544 creator A5007664568 @default.
• W4322760544 creator A5021907714 @default.
• W4322760544 creator A5054560090 @default.
• W4322760544 creator A5060759192 @default.
• W4322760544 creator A5066861338 @default.
• W4322760544 creator A5069246243 @default.
• W4322760544 creator A5078721850 @default.
• W4322760544 date "2023-03-01" @default.
• W4322760544 modified "2023-09-27" @default.
• W4322760544 title "Abstract OT3-31-01: The Amelia-1 Study: A phase 1b/2 trial of evexomostat (SDX-7320) plus fulvestrant (Faslodex®) and alpelisib (Piqray®) in patients with advanced breast cancer at risk for alpelisib (Piqray)-induced hyperglycemia" @default.
• W4322760544 doi "https://doi.org/10.1158/1538-7445.sabcs22-ot3-31-01" @default.
• W4322760544 hasPublicationYear "2023" @default.
• W4322760544 type Work @default.
• W4322760544 citedByCount "0" @default.
• W4322760544 crossrefType "journal-article" @default.
• W4322760544 hasAuthorship W4322760544A5000260923 @default.
• W4322760544 hasAuthorship W4322760544A5002767668 @default.
• W4322760544 hasAuthorship W4322760544A5007664568 @default.
• W4322760544 hasAuthorship W4322760544A5021907714 @default.
• W4322760544 hasAuthorship W4322760544A5054560090 @default.
• W4322760544 hasAuthorship W4322760544A5060759192 @default.
• W4322760544 hasAuthorship W4322760544A5066861338 @default.
• W4322760544 hasAuthorship W4322760544A5069246243 @default.
• W4322760544 hasAuthorship W4322760544A5078721850 @default.
• W4322760544 hasConcept C121608353 @default.
• W4322760544 hasConcept C126322002 @default.
• W4322760544 hasConcept C134018914 @default.
• W4322760544 hasConcept C143998085 @default.
• W4322760544 hasConcept C207103383 @default.
• W4322760544 hasConcept C2777176818 @default.
• W4322760544 hasConcept C2777180221 @default.
• W4322760544 hasConcept C2777391703 @default.
• W4322760544 hasConcept C2779306644 @default.
• W4322760544 hasConcept C2780482068 @default.
• W4322760544 hasConcept C2780988686 @default.
• W4322760544 hasConcept C44249647 @default.
• W4322760544 hasConcept C530470458 @default.
• W4322760544 hasConcept C555293320 @default.
• W4322760544 hasConcept C71924100 @default.
• W4322760544 hasConceptScore W4322760544C121608353 @default.
• W4322760544 hasConceptScore W4322760544C126322002 @default.
• W4322760544 hasConceptScore W4322760544C134018914 @default.
• W4322760544 hasConceptScore W4322760544C143998085 @default.
• W4322760544 hasConceptScore W4322760544C207103383 @default.
• W4322760544 hasConceptScore W4322760544C2777176818 @default.
• W4322760544 hasConceptScore W4322760544C2777180221 @default.
• W4322760544 hasConceptScore W4322760544C2777391703 @default.
• W4322760544 hasConceptScore W4322760544C2779306644 @default.
• W4322760544 hasConceptScore W4322760544C2780482068 @default.
• W4322760544 hasConceptScore W4322760544C2780988686 @default.
• W4322760544 hasConceptScore W4322760544C44249647 @default.
• W4322760544 hasConceptScore W4322760544C530470458 @default.
• W4322760544 hasConceptScore W4322760544C555293320 @default.
• W4322760544 hasConceptScore W4322760544C71924100 @default.
• W4322760544 hasIssue "5_Supplement" @default.
• W4322760544 hasLocation W43227605441 @default.
• W4322760544 hasOpenAccess W4322760544 @default.
• W4322760544 hasPrimaryLocation W43227605441 @default.
• W4322760544 hasRelatedWork W1991367927 @default.
• W4322760544 hasRelatedWork W2010484394 @default.
• W4322760544 hasRelatedWork W2012273189 @default.
• W4322760544 hasRelatedWork W2014369012 @default.
• W4322760544 hasRelatedWork W2032225465 @default.
• W4322760544 hasRelatedWork W2056849036 @default.
• W4322760544 hasRelatedWork W2094672900 @default.
• W4322760544 hasRelatedWork W2151350502 @default.
• W4322760544 hasRelatedWork W2410789767 @default.
• W4322760544 hasRelatedWork W2418646588 @default.
• W4322760544 hasVolume "83" @default.
• W4322760544 isParatext "false" @default.
• W4322760544 isRetracted "false" @default.
• W4322760544 workType "article" @default.